Related references
Note: Only part of the references are listed.Oncology nurse phone calls halve the risk of reduced dose intensity of immunochemotherapy: results of the randomized FORTIS study in chronic lymphocytic leukemia.
Loic Ysebaert et al.
ANNALS OF HEMATOLOGY (2019)
Hypertension and incident cardiovascular events following ibrutinib initiation
Tyler Dickerson et al.
BLOOD (2019)
How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia
Deborah M. Stephens et al.
BLOOD (2019)
Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia
Lindsey E. Roeker et al.
JAMA NETWORK OPEN (2019)
Ibrutinib discontinuation in Waldenstrom macroglobulinemia: Etiologies, outcomes, and IgM rebound
Joshua N. Gustine et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib
David Ghez et al.
BLOOD (2018)
Single-agent ibrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience
Susan O'Brien et al.
BLOOD (2018)
Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer
Tilly Varughese et al.
CLINICAL INFECTIOUS DISEASES (2018)
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
Anthony R. Mato et al.
HAEMATOLOGICA (2018)
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding
Giuseppe Boriani et al.
HEMATOLOGICAL ONCOLOGY (2018)
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
Anthony R. Mato et al.
HAEMATOLOGICA (2018)
Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways
Georgios Chamilos et al.
CLINICAL INFECTIOUS DISEASES (2018)
Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice
Heidi D. Finnes et al.
LEUKEMIA & LYMPHOMA (2017)
LONG-TERM EFFICACY AND SAFETY IN THE RESONATE STUDY: IBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH UP TO FOUR YEARS FOLLOW-UP
M. Montillo et al.
HEMATOLOGICAL ONCOLOGY (2017)
Fungal infections in patients treated with ibrutinib: two unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis
Marine Baron et al.
LEUKEMIA & LYMPHOMA (2017)
Risk of Atrial Fibrillation and Bleeding Diathesis Associated With Ibrutinib Treatment: A Systematic Review and Pooled Analysis of Four Randomized Controlled Trials
Seongseok Yun et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
Real-world results of ibrutinib in relapsed/refractory CLL in France: Early results on a large series of 428 patients
Loic Ysebaert et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib
Jeffrey A. Jones et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma
Michail S. Lionakis et al.
CANCER CELL (2017)
Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group
Anne-Sophie Michallet et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis
Francois Caron et al.
BLOOD ADVANCES (2017)
Atrial fibrillation associated with ibrutinib in Waldenstrom macroglobulinemia
Joshua N. Gustine et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis
Darryl P. Leong et al.
BLOOD (2016)
Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study
Philip A. Thompson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group
Maria Winqvist et al.
HAEMATOLOGICA (2016)
Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients
HAEMATOLOGICA (2016)
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase study
Martin Dreyling et al.
LANCET (2016)
Ibrutinib-related atrial fibrillation in patients with mantle cell lymphoma
Hun Ju Lee et al.
LEUKEMIA & LYMPHOMA (2016)
Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group
Maria Winqvist et al.
HAEMATOLOGICA (2016)
Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients
HAEMATOLOGICA (2016)
Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia
Carole Bitar et al.
JAMA DERMATOLOGY (2016)
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
Michael L. Wang et al.
BLOOD (2015)
Ambulatory Medical Assistance - After Cancer (AMA-AC): A model for an early trajectory survivorship survey of lymphoma patients treated with anthracycline-based chemotherapy
Gisele Compaci et al.
BMC CANCER (2015)
Adverse drug reactions in special populations - the elderly
E. A. Davies et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Ibrutinib in Previously Treated Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions
Marie Levade et al.
BLOOD (2014)
Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling
Julie R. McMullen et al.
BLOOD (2014)
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
J. C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Effectiveness of telephone support during chemotherapy in patients with diffuse large B cell lymphoma: The Ambulatory Medical Assistance (AMA) experience
Gisele Compaci et al.
INTERNATIONAL JOURNAL OF NURSING STUDIES (2011)
Under-reporting of adverse drug reactions - A systematic review
Lorna Hazell et al.
DRUG SAFETY (2006)
Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications
AA Mangoni et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Share Paper
